VVOS — Vivos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1716166 ·
Last close
$0.08
Market Cap
$1.60M
52W High
$2.69
52W Low
$0.07
ADV30
5,825,694
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,153,000 | 2,953,000 | -4,825,000 | -5,481,000 | 24,144,000 | 1,774,000 | 28,130,000 |
| Mar 2026 | 5,141,000 | 3,059,000 | -6,615,000 | -7,682,000 | 25,043,000 | 2,110,000 | 26,310,000 |
| Dec 2025 | 3,824,000 | 2,988,000 | -6,382,000 | -6,954,000 | 25,152,000 | 2,029,000 | 26,702,000 |
| Sep 2025 | 6,783,000 | 3,937,000 | -4,734,000 | -5,400,000 | 25,644,000 | 3,087,000 | 23,112,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,131,000
Investing CF
$-1,932,000
Financing CF
$16,435,000
CapEx
$-2,736,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.87
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-138,520,000
Inventory
—
Receivables
$1,438,000
ST Investments
—
EBIT TTM
$-22,556,000
Pretax Income TTM
$-25,628,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,902,000
EBITDA
$-20,763,000
Free Cash Flow
$-8,534,250
Enterprise Value
$15,366,716
Total Cash
$1,774,000
Total Debt
$12,505,000
Shares Out
20,118,023
Trailing EPS
$-1.88
Book Value
$-0.34
ROE
-8585.3%
ROA
-56.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,443,000 | -19,894,000 | -21,230,000 | 25,152,000 | 26,702,000 | -1,490,000 | -15,263,000 |
| Dec 2024 | 15,031,000 | -11,171,000 | -11,136,000 | 15,284,000 | 7,330,000 | 7,954,000 | -12,691,000 |
| Dec 2023 | 13,801,000 | -17,296,000 | -13,583,000 | 10,730,000 | 10,319,000 | 411,000 | -11,946,000 |
| Dec 2022 | 16,024,000 | -25,031,000 | -23,845,000 | 13,720,000 | 8,919,000 | 4,801,000 | -19,587,000 |
TTM Snapshot
Revenues TTM
$20,901,000
NetIncome TTM
$-25,456,000
OpCashFlow TTM
—
Assets (Latest)
$24,144,000
Forward EPS
$-0.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUPR | Cuprina Holdings (Cayman) LTD | $1.56M | $1.69 | — |
| VYCO | VYCOR MEDICAL INC | $1.47M | $0.04 | — |
| ESMC | ESCALON MEDICAL CORP | $1.40M | $0.19 | — |
| NXL | Nexalin Technology, Inc. | $1.85M | $1.50 | — |
| CODX | Co-Diagnostics, Inc. | $2.06M | $0.20 | — |
News headlines (Yahoo Finance, 1h cache)
Vivos Therapeutics Inc (VVOS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Payer ...
2026-11-18 17:01 · Yahoo
Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-16 23:55 · Yahoo
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
2026-11-16 23:31 · Yahoo
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
2026-10-29 14:52 · Yahoo
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
2026-10-21 11:00 · Yahoo
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
2026-10-19 21:01 · Yahoo
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
2026-10-15 12:45 · Yahoo
Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives Accelerate
2026-09-29 14:42 · Yahoo
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
2026-09-29 12:45 · Yahoo
Vivos Therapeutics Announces Material Debt Reduction
2026-09-08 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.